Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.19 USD
Change Today +0.70 / 6.67%
Volume 887.8K
LBIO On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

lion biotechnologies inc (LBIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $15.03
52 Week Low
11/18/14 - $4.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

lion biotechnologies inc (LBIO) Related Businessweek News

No Related Businessweek News Found

lion biotechnologies inc (LBIO) Details

Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product includes LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors for the treatment of patients with refractory metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. to manufacture, package, ship, and perform quality assurance and quality control of TIL therapy. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in Woodland Hills, California.

14 Employees
Last Reported Date: 03/16/15
Founded in 2007

lion biotechnologies inc (LBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $336.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $225.0K
Vice President of Manufacturing
Total Annual Compensation: $290.2K
Chief Scientific Officer
Total Annual Compensation: $187.2K
Compensation as of Fiscal Year 2014.

lion biotechnologies inc (LBIO) Key Developments

Lion Biotechnologies, Inc. Presents at Piper Jaffray GenomeRx Symposium, May-20-2015

Lion Biotechnologies, Inc. Presents at Piper Jaffray GenomeRx Symposium, May-20-2015. Venue: The New York Palace Hotel, New York, New York, United States. Presentation Date & Speakers: May-20-2015, Elma S. Hawkins, Chief Executive Officer, President and Director.

Lion Biotechnologies, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

Lion Biotechnologies, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Elma S. Hawkins, Chief Executive Officer, President and Director.

Lion Biotechnologies, Inc. Announces Publication of Data from Clinical Study of Metastatic Cervical Cancer Patients Treated with HPV-TIL

Lion Biotechnologies, Inc. announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncologyin an article titled "Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells". Data from the trial showed objective responses, including durable, complete regressions, in patients after a single infusion of HPV-TIL. The trial was designed to determine if the infusion of human papillomavirus tumor-infiltrating lymphocytes (HPV-TIL) could induce regression of advanced HPV-positive cancers. Of the nine metastatic cervical cancer patients who were enrolled and treated with HPV-TIL, three patients experienced objective tumor responses, two of whom experienced complete, ongoing remissions of 22 and 15 months, respectively. The other patient demonstrated a partial response of three months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LBIO:US $11.19 USD +0.70

LBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation LBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LION BIOTECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at